文献

アルゴリズム・手術文献

1） 日本胃癌学会編: 胃癌取扱い規約，第15版，2017，金原出版，東京．
2） TNM Classification of Malignant Tumours Eighth Edition. Ed: Brierley JD, Gospodarowicz MK, Wittekind C. 2017, Wiley Blackwell.
3） Kaminishi M, Yamaguchi H, Shimizu N, et al: Stomach-partitioning gastrojejunostomy for unresectable gastric carcinoma. Arch Surg 1997; 132: 184‒7.
4） Fujitani K, Yang HK, Mizusawa J, et al: Gastrectomy plus chemotherapy versus hemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial. Lancet Oncol 2016; 17: 309‒18.
5） Sano T, Sasako M, Mizusawa J, et al: Stomach Cancer Study Group of the Japan Clinical Oncology Group: Randomized Controlled Trial to Evaluate Splenectomy in Total Gastrectomy for Proximal Gastric Carcinoma. Ann Surg. 2017; 265: 277‒83.
6） Tokunaga M, Ohyama S, Hiki N, et al: Therapeutic value of lymph node dissection in advanced gastric cancer with macroscopic duodenum invasion: is the posterior pancreatic head lymph node dissection beneficial? Ann Surg Oncol 2009; 16: 1241‒6.
7） Yamashita H, Seto Y, Sano T, et al: Japanese Gastric Cancer Association and the Japan Esophageal Society: Results of a nation-wide retrospective study of lymphadenectomy for esophagogastric junction carcinoma. Gastric Cancer 2017; 20 (Suppl 1): 69‒83.
8） Terashima M, Doki Y, Kurokawa Y, et al: Primary results of a phase III trial to evaluate bursectomy for patients with subserosal/serosal gastric cancer (JCOG1001). J Clin Oncol 2017; 35: 4 (suppl; abstr 5).
9） Sasako M, Sano T, Yamamoto S, et al: Japan Clinical Oncology Group (JCOG9502): Left thoracoabdominal approach versus abdominal-transhiatal approach for gastric cancer of the cardia or subcardia: a randomised controlled trial. Lancet Oncol 2006; 7: 644‒51.
10） Katai H, Sasako M, Fukuda H, et al: Safety and feasibility of laparoscopy-assisted distal gastrectomy with suprapancreatic nodal dissection for clinical stage I gastric cancer: a multicenter phase II trial (JCOG 0703). Gastric Cancer 2010; 13: 238‒44.
11） Nakamura K, Katai H, Mizusawa J, et al: A phase III study of laparoscopy-assisted versus open distal gastrectomy with nodal dissection for clinical stage IA/IB gastric Cancer (JCOG0912). Jpn J Clin Oncol 2013; 43: 324‒7.
12） Kim HH, Hyung WJ, Cho GS, et al: Morbidity and mortality of laparoscopic gastrectomy versus open gastrectomy for gastric cancer: an interim report―a phase III multicenter, prospective, randomized Trial (KLASS Trial). Ann Surg 2010; 251: 417‒20.
13） Inaki N, Etoh T, Ohyama T, et al: Multi-institutional, prospective, phase II feasibility study of laparoscopy-assisted distal gastrectomy with D2 lymph node dissection for locally advanced gastric cancer (JLSSG0901). World J Surg 2015; 39: 2734‒41.

内視鏡文献

14） Tada M, Murakami A, Karita M, et al: Endoscopic resection of early gastric cancer. Endos-copy 1993; 25: 445‒50.
15） Inoue H, Takeshita K, Hori H, et al: Endoscopic mucosal resection with a cap-fitted panendoscope for esophagus, stomach, and colon mucosal lesions. Gastrointest Endosc 1993; 39: 58‒62.
16） Hirao M, Masuda K, Asanuma T, et al: Endoscopic resection of early gastric cancer and other tumors with local injection of hypertonic saline-epinephrine. Gastrointest Endosc 1988; 34: 264‒9.
17） Ono H, Kondo H, Gotoda T et al: Endoscopic mucosal resection for treatment of early gastric cancer. Gut 2001; 48: 225‒9.
18） Ono H, Hasuike N, Inui T, et al: Usefulness of a novel electrosurgical knife, the insulationtipped diathermic knife-2, for endoscopic submucosal dissection of early gastric cancer. Gastric Cancer 2008; 11: 47‒52.
19） 下田忠和，九嶋亮治，小野裕之: ESD標本における消化性潰瘍と生検瘢痕との鑑別．胃と腸 2013; 48: 16‒24.
20） Gotoda T, Yanagisawa A, Sasako M, et al: Incidence of lymph node metastasis from early gastric cancer: estimation with a large number of cases at two large centers. Gastric Cancer 2000; 3: 219‒25.
21） Gotoda T, Iwasaki M, Kusano C, et al: Endoscopic resection of early gastric cancer treated by guideline and expanded National Cancer Centre criteria. Br J Surg 2010; 97: 868‒71.
22） Hasuike N, Ono H, Boku N, et al: A non-randomized confirmatory trial of an expanded indication for endoscopic submucosal dissection for intestinal-type gastric cancer (cT1a): the Japan Clinical Oncology Group study (JCOG0607). Gastric Cancer 2017 Feb 21. doi: 10.1007/s10120-017-0704-y. [Epub ahead of print]
23） Takizawa K, Takashima A, Kimura A, et al: A phase II clinical trial of endoscopic submucosal dissection for early gastric cancer of undifferentiated type: Japan Clinical Oncology Group study JCOG1009/1010. Jpn J Clin Oncol 2013; 43: 87‒91.
24） Sekiguchi M, Suzuki H, Oda I, et al: Favorable long-term outcomes of endoscopic submucosal dissection for locally recurrent early gastric cancer after endoscopic resection. Endoscopy 2013; 45: 708‒13.
25） Jung DH, Bae YS, Yoon SO, et al: Poorly differentiated carcinoma component in submucosal layer should be considered as an additional criterion for curative endoscopic resection of early gastric cancer. Ann Surg Oncol 2015; 22: S772‒7.
26） Nakajima T, Oda I, Gotoda T, et al: Metachronous gastric cancers after endoscopic resection: how effective is annual endoscopic surveillance? Gastric Cancer 2006; 9: 93‒8.
27） Hirasawa T, Gotoda T, Miyata S, et al: Incidence of lymph node metastasis and the feasibility of endoscopic resection for undifferentiated-type early gastric cancer. Gastric Cancer 2009; 12: 148‒52.
28） Gotoda T, Sasako M, Ono H, et al: Evaluation of the necessity for gastrectomy with lymph node dissection for patients with submucosal invasive gastric cancer. Br J Surg 2001; 88: 444‒9.
29） Fukase K, Kato M, Kikuchi S, et al: Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: An open-label, randomised controlled trial. Lancet 2008; 372: 392‒7.
30） Choi J, Kim SG, Yoon H, et al: Eradication of Helicobacter pylori after endoscopic resection of gastric tumors does not reduce incidence of metachronous gastric carcinoma. Clin Gastroenterol Hepatol 2014; 12: 793‒800.
31） Eguchi T, Gotoda T, Oda I, et al: Is endoscopic one-piece mucosal resection essential for early gastric cancer? Dig Endosc 2003; 15: 113‒6.
32） 日本胃癌学会編: 胃癌治療ガイドライン医師用2010年10月改訂，第3版，2010，金原出版，東京，p30．
33） Hatta W, Gotoda T, Oyama T, et al: A Scoring System to Stratify Curability after Endoscopic Submucosal Dissection for Early Gastric Cancer: “eCura system”. Am J Gastroenterol 2017; 112: 874‒81.

化学療法文献

34） Ohtsu A, Shimada Y, Shirao K, et al: Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol 2003; 21: 54‒9.
35） Bang YJ, Van Cutsem E, Feyereislova A, et al: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376: 687‒97.
36） Murad AM, Santiago FF, Petroianu A, et al: Modified therapy with 5-fluorouracil, doxorubicin and methotrexate in advanced gastric cancer. Cancer 1993; 72: 37‒41.
37） Glimelius B, Hoffman K, Haglund U, et al: Initial or delayed chemotherapy with best supportive care in advanced gastric cancer. Ann Oncol 1994; 5: 189‒90.
38） Pyrhönen S, Kuitunen T, Nyandoto P, et al: Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 1995; 71: 587‒91.
39） Boku N, Yamamoto S, Shirao K, et al: Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol 2009; 10: 1063‒9.
40） Koizumi W, Narahara H, Hara T, et al: S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 2008; 9: 215‒21.
41） Ohtsu A, Shah MA, Van Cutsem E, et al: Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol 2011; 29: 3968‒76.
42） Cunningham D, Starling N, Rao S, et al: Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008; 358: 36‒46.
43） Yamada Y, Higuchi K, Nishikawa K, et al: Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer. Ann Oncol 2015; 26: 141‒8.
44） Shah MA, Bang YJ, Lordick F, et al: Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma: The METGastric Randomized Clinical Trial. JAMA Oncol 2017; 3: 620‒7.
45） Yoon HH, Bendell JC, Braiteh FS, et al: Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial. Ann Oncol 2016; 27: 2196‒203.
46） Koizumi W, Kim YH, Fujii M, et al: Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START). J Cancer Res Clin Oncol 2014; 140: 319‒28.
47） Narahara H, Iishi H, Imamura H, et al: Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastriccancer (study GC0301/TOP-002). Gastric Cancer 2011; 14: 72‒80.
48） Van Cutsem E, Moiseyenko VM, Tjulandin S, et al: Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 2006; 24: 4991‒7.
49） Kurokawa Y, Sugimoto N, Miwa H, et al: Phase II study of trastuzumab in combination with S-1 plus cisplatin in HER2-positive gastric cancer (HERBIS-1). Br J Cancer 2014; 110: 1163‒8.
50） Miura Y, Sukawa Y, Hironaka S, et al: Five-weekly S-1 plus cisplatin therapy combined with trastuzumab therapy in HER2-positive gastric cancer: a phase II trial and biomarker study (WJOG7212G). Gastric Cancer 2017 May 11. doi: 10.1007/s10120-017-0725-6. [Epub ahead of print]
51） Ryu MH, Yoo C, Kim JG, et al: Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer. Eur J Cancer 2015; 51: 482‒8.
52） Shinozaki K, Yuki S, Kashiwada T, et al: A phase II study (KSCC/HGCSG/CCOG/Per-SeUS1501B) of trastuzumab plus S-1 and oxaliplatin for HER2-positive advanced gastric cancer. J Clin Oncol 2017; 35: 15 (suppl; abstr 4059).
53） Thuss-Patience PC, Kretzschmar A, Bichev D, et al: Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer―a randomized phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer 2011; 47: 2306‒14.
54） Kang JH, Lee SI, Lim DH, et al: Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol 2012; 30: 1513‒8.
55） Ford HE, Marshall A, Bridgewater JA, et al: Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. Lancet Oncol 2014; 15: 78‒86.
56） Hironaka S, Ueda S, Yasui H, et al: Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. J Clin Oncol 2013; 31: 4438‒44.
57） Wilke H, Muro K, Van Cutsem E et al: Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol 2014; 15: 1224‒35.
58） Shitara K, Takashima A, Fujitani K, et al: Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial. Lancet Gastroenterol Hepatol 2017; 2: 277‒87.
59） Sakuramoto S, Sasako M, Yamaguchi T, et al: Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007; 357: 1810‒20.
60） Sasako M, Sakuramoto S, Katai H, et al: Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol 2011; 29: 4387‒93.
61） Takahari D, Hamaguchi T, Yoshimura K, et al: Feasibility study of adjuvant chemotherapy with S-1 plus cisplatin for gastric cancer. Cancer Chemother Pharmacol 2011; 67: 1423‒8.
62） Bang YJ, Kim YW, Yang HK, et al: Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet 2012; 379: 315‒21.